Caladrius Biosciences Inc., of Basking Ridge, N.J., said the University of California San Francisco Benioff Children's Hospital, University of Florida Diabetes Institute and the Harold Schnitzer Diabetes Health Center at Oregon Health & Science University opened to enroll subjects for the company's phase II trial of CLBS03, which consists of autologous expanded regulatory T cells, to treat recent-onset type 1 diabetes.